HKSE - Delayed Quote HKD

Zai Lab Limited (9688.HK)

22.650
+0.050
+(0.22%)
At close: 4:08:22 PM GMT+8
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
418,326
398,988
266,719
215,040
144,312
Cost of Revenue
152,888
147,860
95,816
74,018
52,239
Gross Profit
265,438
251,128
170,903
141,022
92,073
Operating Expense
528,162
525,075
545,043
533,908
788,024
Operating Income
-262,724
-273,947
-374,140
-392,886
-695,951
Net Non Operating Interest Income Expense
32,725
34,851
39,797
14,582
2,190
Other Income Expense
-22,071
-18,007
-277
-64,761
-9,653
Pretax Income
-252,070
-257,103
-334,620
-443,065
-703,414
Tax Provision
0
0
0
0
0
Earnings from Equity Interest Net of Tax
--
0
0
-221
-1,057
Net Income Common Stockholders
-252,070
-257,103
-334,620
-443,286
-704,471
Diluted NI Available to Com Stockholders
-252,070
-257,103
-334,620
-443,286
-704,471
Basic EPS
-0.25
-0.26
-0.35
-0.46
-0.76
Diluted EPS
-0.25
-0.26
-0.35
-0.46
-0.76
Basic Average Shares
1,016,397.615
989,477.730
966,394.130
958,067.140
929,921.120
Diluted Average Shares
1,016,397.615
989,477.730
966,394.130
958,067.140
929,921.120
Total Operating Income as Reported
-268,119
-282,117
-366,573
-404,357
-700,064
Total Expenses
681,050
672,935
640,859
607,926
840,263
Net Income from Continuing & Discontinued Operation
-252,070
-257,103
-334,620
-443,286
-704,471
Normalized Income
-239,652
-241,966
-329,770
-386,883
-709,132
Interest Income
36,053
37,105
39,797
14,582
2,190
Interest Expense
3,328
2,254
0
0
0
Net Interest Income
32,725
34,851
39,797
14,582
2,190
EBIT
-248,742
-254,849
-334,620
-443,065
-695,951
EBITDA
-236,440
-242,993
-325,591
-434,838
-689,464
Reconciled Cost of Revenue
152,888
147,860
95,816
74,018
52,239
Reconciled Depreciation
12,302
11,856
9,029
8,227
6,487
Net Income from Continuing Operation Net Minority Interest
-252,070
-257,103
-334,620
-443,286
-704,471
Total Unusual Items Excluding Goodwill
-12,418
-15,137
-4,850
-56,403
4,661
Total Unusual Items
-12,418
-15,137
-4,850
-56,403
4,661
Normalized EBITDA
-224,022
-227,856
-320,741
-378,435
-694,125
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 9/28/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

1952.HK Everest Medicines Limited
45.750
+0.33%
 
2105.HK Laekna, Inc.
13.840
-4.02%
 
1801.HK INNOVENT BIO
50.100
+0.20%
 
9966.HK Alphamab Oncology
6.610
+0.15%
 
9995.HK RemeGen Co., Ltd.
41.350
+5.48%
 
1477.HK OCUMENSION-B
5.290
+1.54%
 
2157.HK Lepu Biopharma Co., Ltd.
4.340
+1.64%
 
1530.HK 3SBIO
11.560
+0.52%
 
1877.HK JUNSHI BIO
14.720
+4.25%
 
2171.HK CARsgen Therapeutics Holdings Limited
18.340
-3.88%